Dalmia Bharat Sugar & Industries Ltd
DALMIASUGDalmia Bharat Sugar & Industries Ltd's price has outrun its earnings. −5.5% in a year against EPS −35.2% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −5.5% in a year while annual EPS moved −35.2% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is topping out (3 weeks in) while the P/E sits at the 75th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −47.7% year on year, and 45% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Dalmia Bharat Sugar & Industries Ltd trades at ₹351, losing momentum at the top and 3 weeks into that stage. That is +1.8% against its own 200-day average. It sits at 62% of a 52-week range of ₹274 to ₹398. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is losing momentum at the top — week 3 of stage 3, confirmed. At ₹351 it trades +1.8% versus its 200-day average and sits at 62% of its 52-week range (₹274–₹398).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +220% while the NIFTY 500 moved +268% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Dalmia Bharat Sugar & Industries Ltd trades at 12.3× P/E, at the pricey end of its own range (75th percentile). Its long-run median P/E is 10.0×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.3× is at the pricey end of its own range (75th percentile), against a long-run median of 10.0× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −35.2% against a −5.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −6.1%/yr price move, ~−3.1%/yr came from earnings growth and ~−3.0 pp from the multiple (compressing); over 10y, of the +8.4%/yr price move, ~+16.7%/yr came from earnings growth and ~−8.3 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Dalmia Bharat Sugar & Industries Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 9.6% — the per-curve reads carry the story. The read is built from 11 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −2.9% | +3.6% | +6.1% | +12.0% |
| Profit | −35.5% | −1.9% | −2.7% | +15.1% |
| EPS | −35.2% | −1.8% | −2.6% | +15.0% |
| Share price | −5.5% | −2.1% | −6.1% | +8.4% |
4-Factor Sector Score
54.2/100 — rank 6 of 20 in Sugar · 96% evidence confidence
Dalmia Bharat Sugar & Industries Ltd scores 54.2 out of 100 against the 20 companies it is compared with in Sugar, ranking 6. Price leads the evidence: RS versus the benchmark is 2.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 9.6 + 13.1 + 14.3 + 17.2 = 54.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Dalmia Bharat Sugar & Industries Ltd reported ₹991 Cr of revenue in the Mar 26 quarter, −2.5% year on year. Over 10 years it has compounded at 12.0% a year. The last full year, FY26, came in at ₹3,617 Cr. The last four reported quarters add to ₹3,619 Cr.
FY26 revenue came in at ₹3,617 Cr (−2.9% on the year), capping 10 years at 12.0% compound. The latest quarter (Mar 26) printed ₹991 Cr, −2.5% year on year.
Pace check: the last four quarters averaged −3.6% growth against the decade's 12.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −3.2% over the last 4 quarters against +11.7%/yr over the last 8 — rolling over; TTM profit −37.7% vs −6.9%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Dalmia Bharat Sugar & Industries Ltd's operating margin is 17.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 22.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 17.0%, −2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–22.0%.
Why the margin moved: operating margin went +5.1 pp year on year while gross margin went +4.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Dalmia Bharat Sugar & Industries Ltd earned ₹104 Cr of net profit in the Mar 26 quarter, −47.7% year on year. Full-year FY26 profit was ₹236 Cr. The 10-year compound rate is 15.1%. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned ₹199 Cr.
Mar 26 profit was ₹104 Cr, −47.7% year on year. On the full year, FY26 printed ₹236 Cr (−35.5%), and the 10-year compound rate is 15.1%.
🚨 Why profit moved: revenue contributed −2.5% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −30.9% vs revenue −3.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 45% of Dalmia Bharat Sugar & Industries Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹219 Cr of operating cash against ₹236 Cr of profit. After ₹124 Cr of capital spending, ₹95.0 Cr was left as free cash.
FY26: operating cash of ₹219 Cr against reported profit of ₹236 Cr, leaving free cash of ₹95.0 Cr after ₹124 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 45% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 45%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Dalmia Bharat Sugar & Industries Ltd's cash conversion cycle runs 230 days in FY26, down from 237 days in FY21. Capital spending ran ₹552 Cr over the last 3 years. At FY26 sales of ₹3,617 Cr each day of that cycle holds about ₹9.9 Cr, so roughly ₹2,279 Cr sits inside the business at any moment.
FY26: debtors at 18 days, inventory at 233 days — roughly 7.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 230 days, tighter than FY21's 237.
The full loop: cash goes out to suppliers and production on day 0; stock waits 233 days to sell; customers pay about 18 days after that; and suppliers themselves are paid at 21 days — netting out to the 230-day cycle.
In money terms: at FY26 sales of ₹3,617 Cr, each day of the cycle holds about ₹9.9 Cr — so the 230-day loop keeps roughly ₹2,279 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹552 Cr over the last 3 fiscal years against ₹394 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹47.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Dalmia Bharat Sugar & Industries Ltd earns a ROCE of 8% in FY26. That is up from a trough of 5% in FY15. Return on invested capital clears the cost of that capital by −6.2 percentage points, so growth here is not yet paying for the capital it uses.
FY26 ROCE is 8%, recovered from a FY15 trough of 5% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.5% net margin × 0.66× asset turns × 1.70× balance-sheet leverage ≈ 7.3% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 5.8% − 12.0% = a −6.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Dalmia Bharat Sugar & Industries Ltd carries total debt of ₹1,803 Cr against shareholder equity of ₹3,235 Cr as of Mar 26, a debt-to-equity of 0.56. On the annual view that ratio went from 0.35 in FY22 to 0.56 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹1,803 Cr against shareholder equity of ₹3,235 Cr — a debt-to-equity of 0.56. On the annual view, debt-to-equity went from 0.35 (FY22) to 0.56 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Dalmia Bharat Sugar & Industries Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.2 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.4 points over 8 quarters to 0.5%; Domestic institutions: +0.2 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 74.9%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Dalmia Bharat Sugar & Industries Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Andhra Sugars LtdANDHRSUGAR | 65.7/100Favorable setup83% evidence | FADING | 26.7/35 Revenue 22.1% · PAT 100% · OPM change -1.8 pp 83% evidence | 12.9/25 ROCE 8.5% · OPM 7.5% 95% evidence | 13.0/20 P/E 11.2× · PEG — 50% evidence | 13.1/20 RS sector 8.6% · RS bench 1.9% · 1Y 2.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 12.9 + 13 + 13.1 = 65.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2DCM Shriram LtdDCMSHRIRAM | 60.5/100Mixed-positive evidence100% evidence | ASLEEP | 23.8/35 Revenue 11.1% · PAT 100% · OPM change 0 pp 100% evidence | 13.0/25 ROCE 11.5% · OPM 9% 100% evidence | 16.8/20 P/E 11.8× · PEG 0.44 100% evidence | 6.9/20 RS sector -6.5% · RS bench -12% · 1Y -26%0 of 12 weeks ahead 100% evidence |
| Exact sum: 23.8 + 13 + 16.8 + 6.9 = 60.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -6.5% and the one-year return is -26%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Uttam Sugar Mills LtdUTTAMSUGAR | 58.4/100Mixed-positive evidence70% evidence | ASLEEP | 23.1/35 Revenue 19.2% · PAT 17.4% · OPM change 1 pp 83% evidence | 17.1/25 ROCE 11.5% · OPM 21% 95% evidence | 11.2/20 P/E 8.4× · PEG — 15% evidence | 7.0/20 RS sector -9.1% · RS bench -8.2% · 1Y -17.3%5 of 10 weeks ahead 70% evidence |
| Exact sum: 23.1 + 17.1 + 11.2 + 7 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4M.V.K. Agro Food Product LtdMVKAGRO | 56.6/100Thin evidence · provisional52% evidence | ASLEEP | 18.2/35 Revenue — · PAT — · OPM change 17 pp 32% evidence | 17.6/25 ROCE 14.4% · OPM 22% 95% evidence | 8.8/20 P/E 35.8× · PEG — 15% evidence | 12.0/20 RS sector 33.8% · RS bench -37.8% · 1Y 47.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 17.6 + 8.8 + 12 = 56.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Bannari Amman Sugars LtdBANARISUG | 55.0/100Mixed-positive evidence96% evidence | BASING | 17.9/35 Revenue 6.9% · PAT 42.3% · OPM change -9.7 pp 88% evidence | 14.9/25 ROCE 9.3% · OPM 1.3% 100% evidence | 9.6/20 P/E 29.5× · PEG 1.75 100% evidence | 12.6/20 RS sector 0.9% · RS bench -5% · 1Y -7.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 14.9 + 9.6 + 12.6 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Dalmia Bharat Sugar & Industries Ltdthis pageDALMIASUG | 54.2/100Mixed-positive evidence96% evidence | ASLEEP | 9.6/35 Revenue -3.2% · PAT -37.7% · OPM change -2 pp 88% evidence | 13.1/25 ROCE 8.2% · OPM 17% 100% evidence | 14.3/20 P/E 12.3× · PEG 0.48 100% evidence | 17.2/20 RS sector 9.6% · RS bench 2.8% · 1Y -7.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 9.6 + 13.1 + 14.3 + 17.2 = 54.2 · Decision use: Price leads the evidence: RS versus the benchmark is 2.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 7Dhampur Sugar Mills LtdDHAMPURSUG | 52.4/100Mixed-positive evidence87% evidence | ASLEEP | 20.5/35 Revenue 1.3% · PAT 36.3% · OPM change 1.3 pp 95% evidence | 8.5/25 ROCE 6.4% · OPM 5.7% 95% evidence | 9.0/20 P/E 12.4× · PEG — 50% evidence | 14.4/20 RS sector 7% · RS bench 0.4% · 1Y -6.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 8.5 + 9 + 14.4 = 52.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8EID Parry (India) LtdEIDPARRY | 50.9/100Mixed-positive evidence72% evidence | ASLEEP | 19.9/35 Revenue 21.9% · PAT -22.2% · OPM change 0 pp 83% evidence | 16.9/25 ROCE 17% · OPM 8% 76% evidence | 9.6/20 P/E 20.6× · PEG — 50% evidence | 4.5/20 RS sector -20.5% · RS bench -18.4% · 1Y -35.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 16.9 + 9.6 + 4.5 = 50.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Balrampur Chini Mills LtdBALRAMCHIN | 50.3/100Mixed-positive evidence96% evidence | BREAKING OUT | 15.3/35 Revenue 15.8% · PAT -13.1% · OPM change -6 pp 88% evidence | 13.2/25 ROCE 9.3% · OPM 18% 100% evidence | 2.4/20 P/E 32.7× · PEG 2.21 100% evidence | 19.4/20 RS sector 24% · RS bench 16.5% · 1Y -0.5%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 13.2 + 2.4 + 19.4 = 50.3 · Decision use: Price leads the evidence: RS versus the benchmark is 16.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Dhampur Bio Organics LtdDBOL | 48.1/100Mixed-negative evidence72% evidence | ASLEEP | 21.0/35 Revenue 8% · PAT 100% · OPM change -0.1 pp 71% evidence | 6.1/25 ROCE 5% · OPM 1.7% 95% evidence | 9.7/20 P/E 25.4× · PEG — 15% evidence | 11.3/20 RS sector 7.7% · RS bench 1% · 1Y 10.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 6.1 + 9.7 + 11.3 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Avadh Sugar & Energy LtdAVADHSUGAR | 47.7/100Mixed-negative evidence83% evidence | BREAKING OUT | 8.9/35 Revenue 2.2% · PAT -34.8% · OPM change -4 pp 83% evidence | 11.6/25 ROCE 6.8% · OPM 18% 95% evidence | 8.1/20 P/E 16.1× · PEG — 50% evidence | 19.1/20 RS sector 24.1% · RS bench 16.2% · 1Y 8.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 11.6 + 8.1 + 19.1 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 16.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 12Bajaj Hindusthan Sugar LtdBAJAJHIND | 47.6/100Mixed-negative evidence90% evidence | ASLEEP | 22.4/35 Revenue -2.2% · PAT 100% · OPM change 4 pp 88% evidence | 9.4/25 ROCE 2.3% · OPM 22% 100% evidence | 11.1/20 P/E 28.5× · PEG 1.32 100% evidence | 4.7/20 RS sector -21% · RS bench -12.7% · 1Y -33.2%6 of 11 weeks ahead 70% evidence |
| Exact sum: 22.4 + 9.4 + 11.1 + 4.7 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Godavari Biorefineries LtdGODAVARIB | 44.3/100Mixed-negative evidence76% evidence | ASLEEP | 20.1/35 Revenue 6.3% · PAT 100% · OPM change -4 pp 83% evidence | 9.2/25 ROCE 6.5% · OPM 15% 95% evidence | 8.7/20 P/E 39.7× · PEG — 15% evidence | 6.3/20 RS sector -2.3% · RS bench -8.3% · 1Y -17.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 9.2 + 8.7 + 6.3 = 44.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Zuari Industries LtdZUARIIND | 43.1/100Mixed-negative evidence62% evidence | ASLEEP | 18.8/35 Revenue 7.7% · PAT 100% · OPM change 1 pp 62% evidence | 8.1/25 ROCE 5.5% · OPM 11% 95% evidence | 11.5/20 P/E 6.6× · PEG — 15% evidence | 4.7/20 RS sector -26.8% · RS bench -10.8% · 1Y -2.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 18.8 + 8.1 + 11.5 + 4.7 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Triveni Engineering and Industries LtdTRIVENI | 36.7/100Mixed-negative evidence82% evidence | ASLEEP | 18.0/35 Revenue 4% · PAT 29.1% · OPM change 1 pp 95% evidence | 9.6/25 ROCE 6.8% · OPM 3.4% 76% evidence | 6.8/20 P/E 18.6× · PEG — 50% evidence | 2.3/20 RS sector -33.2% · RS bench -3.8% · 1Y -39.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 9.6 + 6.8 + 2.3 = 36.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Davangere Sugar Company LtdDAVANGERE | 36.3/100Mixed-negative evidence70% evidence | 14.4/35 Revenue 11.1% · PAT -22.3% · OPM change -6.9 pp 83% evidence | 8.9/25 ROCE 5.6% · OPM 10.1% 95% evidence | 8.5/20 P/E 58.6× · PEG — 15% evidence | 4.5/20 RS sector -25% · RS bench -12.6% · 1Y -47%1 of 8 weeks ahead 70% evidence | |
| Exact sum: 14.4 + 8.9 + 8.5 + 4.5 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Magadh Sugar & Energy LtdMAGADSUGAR | 36.0/100Mixed-negative evidence77% evidence | ASLEEP | 6.4/35 Revenue -5.9% · PAT -41.3% · OPM change -5 pp 83% evidence | 11.9/25 ROCE 7.8% · OPM 27% 95% evidence | 10.1/20 P/E 11.1× · PEG — 50% evidence | 7.6/20 RS sector -19.1% · RS bench -0.8% · 1Y -11.1%2 of 10 weeks ahead 70% evidence |
| Exact sum: 6.4 + 11.9 + 10.1 + 7.6 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Dwarikesh Sugar Industries LtdDWARKESH | 35.1/100Thin evidence · provisional54% evidence | ASLEEP | 16.7/35 Revenue 20.1% · PAT -80% · OPM change -8.2 pp 31% evidence | 3.7/25 ROCE 5% · OPM -7.2% 80% evidence | 9.5/20 P/E 25.6× · PEG — 15% evidence | 5.2/20 RS sector -5.6% · RS bench -11.4% · 1Y -17.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 3.7 + 9.5 + 5.2 = 35.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Shree Renuka Sugars LtdRENUKA | 17.1/100Adverse evidence76% evidence | ASLEEP | 2.4/35 Revenue -15.2% · PAT -80% · OPM change -9.5 pp 88% evidence | 0.6/25 ROCE -3.1% · OPM 1.5% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -12.9% · RS bench -18.2% · 1Y -29.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 2.4 + 0.6 + 10 + 4.1 = 17.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20DCM Shriram Industries LtdDCMSRIND | 43.1/100Thin evidence · provisional48% evidence | 12.3/35 Revenue -3.7% · PAT -50% · OPM change -6.8 pp 45% evidence | 14.0/25 ROCE 13.7% · OPM 1.8% 71% evidence | 8.8/20 P/E 8.2× · PEG — 50% evidence | 8.0/20 RS sector — · RS bench -16.3% · 1Y — 25% evidence | |
| Exact sum: 12.3 + 14 + 8.8 + 8 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Dalmia Bharat Sugar & Industries Ltd's share price today?
Dalmia Bharat Sugar & Industries Ltd trades at ₹351, −5.5% over the past year. The company is valued at ₹2,840 Cr. The stock sits at 62% of its 52-week range of ₹274–₹398, +1.8% versus its 200-day average. On the tape, the price is topping out, 3 weeks in. — as of 31 July 2026.
What were Dalmia Bharat Sugar & Industries Ltd's latest quarterly results?
Dalmia Bharat Sugar & Industries Ltd reported revenue of ₹991 Cr and net profit of ₹104 Cr for the Mar 26 quarter. Revenue fell 2.5% and profit fell 47.7% year on year. Earnings per share were ₹12.91. The operating margin was 17.0%, 2.0 pp lower than a year earlier. — as of 31 July 2026.
What is Dalmia Bharat Sugar & Industries Ltd's revenue?
Dalmia Bharat Sugar & Industries Ltd reported revenue of ₹991 Cr in the Mar 26 quarter, −2.5% year on year. For the full FY26 fiscal year, revenue was ₹3,617 Cr (−2.9%). Over the last 10 years revenue compounded at 12.0% a year. — as of 31 July 2026.
What is Dalmia Bharat Sugar & Industries Ltd's profit?
Dalmia Bharat Sugar & Industries Ltd earned ₹104 Cr of net profit in the Mar 26 quarter, −47.7% year on year. Full-year FY26 profit was ₹236 Cr. The operating margin ran 17.0% in the latest quarter. — as of 31 July 2026.
What is Dalmia Bharat Sugar & Industries Ltd's market cap?
Dalmia Bharat Sugar & Industries Ltd's market capitalisation is ₹2,840 Cr at a share price of ₹351. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Dalmia Bharat Sugar & Industries Ltd's P/E ratio?
Dalmia Bharat Sugar & Industries Ltd trades at a P/E of 12.3×, at the 75th percentile of its own 11-year range, against a long-run median of 10.0×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Dalmia Bharat Sugar & Industries Ltd pay a dividend?
Yes — Dalmia Bharat Sugar & Industries Ltd's dividend payout was 21% of profit in FY26, and it recorded a payout in 11 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Dalmia Bharat Sugar & Industries Ltd overvalued?
On its own history, Dalmia Bharat Sugar & Industries Ltd looks expensive against its own history: its P/E of 12.3× sits at the 75th percentile of its 11-year range (long-run median 10.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Dalmia Bharat Sugar & Industries Ltd growing?
Not right now — Dalmia Bharat Sugar & Industries Ltd's latest numbers are shrinking: latest-quarter revenue −2.5% year on year, profit −47.7%, and the margin −2.0 pp at 17.0%. The 10-year compound rates are 12.0% (revenue) and 15.1% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Dalmia Bharat Sugar & Industries Ltd performing?
Dalmia Bharat Sugar & Industries Ltd is topping out, 3 weeks in. Its latest quarter's revenue fell 2.5% and profit fell 47.7% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Dalmia Bharat Sugar & Industries Ltd in?
Mixed — no clean majority across the growth curves, ROCE holding at 9.6% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth −3.2% latest, profit growth −37.7% latest, eps growth −37.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Dalmia Bharat Sugar & Industries Ltd in an uptrend?
It is stalling — the price is topping out (week 3 of stage 3), trading +1.8% versus its 200-day average and at 62% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Dalmia Bharat Sugar & Industries Ltd beating the market?
Not lately — on a trailing-13-week view Dalmia Bharat Sugar & Industries Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +220% against the NIFTY 500's +268% — behind the index over the full window. — as of 31 July 2026.
Will Dalmia Bharat Sugar & Industries Ltd's share price go up?
This page publishes no price forecast for Dalmia Bharat Sugar & Industries Ltd. What it measures instead: the share price is ₹351, the price is topping out 3 weeks in. Its P/E of 12.3× sits at the 75th percentile of its own 11-year range. — as of 31 July 2026.
Who owns Dalmia Bharat Sugar & Industries Ltd?
Promoters hold 74.9% of Dalmia Bharat Sugar & Industries Ltd, foreign institutions 0.5%, domestic institutions 0.3% and the public 24.1% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Dalmia Bharat Sugar & Industries Ltd have too much debt?
It is moderate — Dalmia Bharat Sugar & Industries Ltd's debt-to-equity is 0.56, and operating profit covers the interest bill 7×. FY26 borrowings were ₹1,803 Cr against equity of ₹3,242 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Dalmia Bharat Sugar & Industries Ltd's capex?
Dalmia Bharat Sugar & Industries Ltd spent ₹552 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹124 Cr, with ₹47.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Dalmia Bharat Sugar & Industries Ltd's cash flow?
Dalmia Bharat Sugar & Industries Ltd generated ₹219 Cr of operating cash flow in FY26 and ₹95.0 Cr of free cash flow after ₹124 Cr of capital spending. Reported profit that year was ₹236 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Dalmia Bharat Sugar & Industries Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 45% of Dalmia Bharat Sugar & Industries Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹219 Cr against reported profit of ₹236 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Dalmia Bharat Sugar & Industries Ltd in its business cycle?
Dalmia Bharat Sugar & Industries Ltd's FY26 operating margin was 12.0%, against a 13-year band of 9.0%–22.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 17.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Dalmia Bharat Sugar & Industries Ltd story?
The sharpest disagreement: the price moved −5.5% in a year while annual EPS moved −35.2% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Dalmia Bharat Sugar & Industries Ltd a stock worth studying right now?
This is not investment advice. The machine read: Dalmia Bharat Sugar & Industries Ltd's price has outrun its earnings. −5.5% in a year against EPS −35.2% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.